Downregulation of HPRT1 reduced resistance, increased apoptotic responses, and impaired tumor growth, indicating that targeting this axis may enhance therapeutic efficacy and serve as a prognostic and therapeutic avenue in OSCC management [207]. The gene discussed is HPRT1; the disease is neoplasm.